EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	3909	((544/319,320,321) or (514/269,272)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/03/20 11:03

NPL

		Results
4.	TITLE-ABSTR-KEY(p38) and TITLE-ABSTR-KEY(copd or chronic obstructive pulmonary disease) *[All Sources(- All Sciences -)]*	44
3.	TITLE-ABSTR-KEY(p38) and TITLE-ABSTR-KEY(asthma) *[All Sources(- All Sciences -)]*	143
2.	TITLE-ABSTR-KEY(p38) and TITLE-ABSTR-KEY(rheumatoid arthritis) *[All Sources(- All Sciences -)]*	138
1.	TITLE-ABSTR-KEY(p38) and TITLE-ABSTR-KEY(arthritis) *[All Sources(- All Sciences -)]*	221

C:\Program Files\Stnexp\Queries\10808146 (b).str



chain nodes :
7 8 9 10 11 17 24 29 42 43 44 49 50 52 59
ring nodes :
1 2 3 4 5 6 18 19 20 21 22 23 30 31 32 33 34 35 36 37 38 39 40 41
53 54 55 56 57 58
chain bonds :
5-7 6-50 8-9 10-11 17-32 17-52 22-24 23-49 29-52 43-44 56-59
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 18-19 18-23 19-20 20-21 21-22 22-23 30-31 30-35 31-32
32-33 33-34 34-35 36-37 36-41 37-38 38-39 39-40 40-41 53-54 53-58 54-55 55-56
56-57 57-58
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-50 8-9 10-11 17-32 17-52 18-19 18-23 19-20
20-21 21-22 22-23 22-24 23-49 29-52 43-44
exact bonds :
56-59
normalized bonds :
30-31 30-35 31-32 32-33 33-34 34-35 36-37 36-41 37-38 38-39 39-40 40-41 53-54
53-58 54-55 55-56 56-57 57-58
isolated ring systems :
containing 1 : 18 :

G1:O,S,CH2,SO2,[*1-*2],[*3-*4]

G2:[*5],[*6]

G3:[*7],[*8],[*9],[*10]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 17:CLASS 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:CLASS
29:CLASS

```
            30:Atom  31:Atom  32:Atom  33:Atom  34:Atom  35:Atom  36:Atom  37:Atom  38:Atom
    39:Atom  40:Atom  41:Atom  42:Atom  43:Atom  44:CLASS  49:CLASS  50:CLASS  52:CLASS
    53:Atom  54:Atom  55:Atom  56:Atom  57:Atom  58:Atom  59:CLASS
Generic attributes :
    42:
    Saturation          : Unsaturated
    43:
    Saturation          : Unsaturated
```

=>
Uploading C:\Program Files\Stnexp\Queries\10808146 (b).str



chain nodes :
7 8 9 10 11 17 24 29 42 43 44 49 50 52 59
ring nodes :
1 2 3 4 5 6 18 19 20 21 22 23 30 31 32 33 34 35 36 37 38 39
40 41 53 54 55 56 57 58
chain bonds :
5-7 6-50 8-9 10-11 17-32 17-52 22-24 23-49 29-52 43-44 56-59
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 18-19 18-23 19-20 20-21 21-22 22-23 30-31
30-35 31-32 32-33 33-34 34-35 36-37 36-41 37-38 38-39 39-40 40-41 53-54
53-58 54-55 55-56 56-57 57-58
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-50 8-9 10-11 17-32 17-52 18-19 18-23
19-20 20-21 21-22 22-23 22-24 23-49 29-52 43-44
exact bonds :
56-59
normalized bonds :
30-31 30-35 31-32 32-33 33-34 34-35 36-37 36-41 37-38 38-39 39-40 40-41
53-54 53-58 54-55 55-56 56-57 57-58

```
isolated ring systems :
containing 1 : 18 :


G1:O,S,CH2,SO2,[*1-*2],[*3-*4]

G2:[*5],[*6]

G3:[*7],[*8],[*9],[*10]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
 11:CLASS  17:CLASS  18:Atom  19:Atom  20:Atom  21:Atom  22:Atom  23:Atom  24:CLASS
 29:CLASS  30:Atom  31:Atom  32:Atom  33:Atom  34:Atom  35:Atom  36:Atom  37:Atom
38:Atom  39:Atom  40:Atom  41:Atom  42:Atom  43:Atom  44:CLASS  49:CLASS  50:CLASS
52:CLASS  53:Atom  54:Atom  55:Atom  56:Atom  57:Atom  58:Atom  59:CLASS
Generic attributes :
42:
Saturation              : Unsaturated
43:
Saturation              : Unsaturated



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=>
```

```
=> d his

     (FILE 'HOME' ENTERED AT 07:50:33 ON 20 MAR 2006)

     FILE 'REGISTRY' ENTERED AT 07:50:41 ON 20 MAR 2006
L1                STRUCTURE UPLOADED
L2              1 S L1 SSS SAM
L3            150 S L1 SSS FUL

=> => s l3
L4            15 L3

=> d l4 1-15 bib,ab,hitstr
```

L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1004710 CAPLUS
DN 143:306330
TI preparation of pyridone and related compounds as melanin concentrating hormone receptor antagonists
IN Otake, Norikazu; Haga, Yuji; Naya, Akira; Mizutani, Sayaka; Kanatani, Akio
PA Banyu Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 233 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005085200	A1	20050915	WO 2005-JP4260	20050304

PI W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI JP 2004-62005 A 20040305
OS MARPAT 143:306330
AB Title compds. I [R1, R2 = H, (un)substituted alkyl, etc.; X1-X3 = (un)substituted methine, etc.; X4-X7 = (un)substituted methine, etc.; Y1 = single bond, etc.; Y2 = (un)substituted alkylene, etc.; Y3 = single bond, etc.; L = (un)substituted methylene; Z1, Z2 = single bond, etc.; Ar = (un)substituted aromatic carbocyclic group, etc.] were prepared For example, exposure of compound II [R = tert-butyldimethylsilyl], e.g., prepared from 4-nitropyridine 1-oxide in 3 steps, to tetrabutylammonium fluoride followed by treating with 2-(dimethylamino)ethanol in the presence of DEAD and PPh3 afforded compound II [R = (CH3)2NCH2CH2]. In MCH (melanin concentrating hormone) binding inhibition assays, the IC50 value of compound II [R = (CH3)2NCH2CH2] was 9.5 nM. Compds. I are claimed useful for the treatment of dibetes, obesity, etc. Formulations are given.
IT **864756-89-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridone and related compds. as melanin concentrating hormone receptor antagonists for treatment of dibetes, obesity, etc.)
RN 864756-89-8 CAPLUS
CN 4(3H)-Pyrimidinone, 6-[(4-fluorophenyl)methoxy]-3-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:177838 CAPLUS
DN 142:280057
TI Preparation of substituted pyridinones as modulators of p38 MAP kinase
IN Devadas, Balekudru; Walker, John; Selness, Shaun R.; Boehm, Terri L.; Durley, Richard C.; Devraj, Rajesh; Hickory, Brian S.; Rucker, Paul V.; Jerome, Kevin D.; Madsen, Heather M.; Alvira, Edgardo; Promo, Michele A.; Blevis-Bal, Radhika M.; Marrufo, Laura D.; Hitchcock, Jeff; Owen, Thomas; Naing, Win; Xing, Li; Shieh, Huey S.; Sambandam, Aruna; Liu, Shuang; Scott, Ian L.; Mcgee, Kevin F.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 968 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005018557	A2	20050303	WO 2004-US26193	20040813
WO 2005018557	A3	20050804		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
NL 1026826	A1	20050216	NL 2004-1026826	20040812
US 2005176775	A1	20050811	US 2004-918826	20040813 ← w ODP
PRAI US 2003-494959P	P	20030813		

OS MARPAT 142:280057
AB Disclosed are title compds. I and their pharmaceutically acceptable salts [R1 H, halo, NO2, CHO, CN, (un)substituted hydroxy/dihydroxy/aryl/alkyl, etc.; R2 = H, OH, halo, (un)substituted alkyl, alkoxy, etc.; R3 = H, halo, (un)substituted aryl/alkoxycarbonyl, arylalkyl, arylthio, etc.; R4 = H, (un)substituted alkyl; R5 = H, aryl, arylalkyl, etc.]. These compds. are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compns. containing the compds., methods of preparing the compds. and methods of treatment
using the compds. are also disclosed. For example, II was prepared, in 3 steps, reacting 4-hydroxy-6-methylpyrone with NH4OH, followed by O-alkylation with 2,4-difluorobenzyl chloride, and bromination with Br2 in AcOH/H2O. Selected I inhibited MKK6-activated human p38α kinase phosphorylation of a biotinylated substrate or human p38α-induced phosphorylation of EGFRP (epidermal growth factor receptor peptide) with an IC50 in the range of 1 μM to 25 μM.
IT **847141-03-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase and TNF activity)
RN 847141-03-1 CAPLUS

CN Benzoic acid, 3-[[4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:17019 CAPLUS
DN 142:107448
TI Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
IN Roark, William Howard
PA Warner-Lambert Company LLC, USA
SO U.S. Pat. Appl. Publ., 44 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005004177	A1	20050106	US 2004-883899	20040702
WO 2005002585	A1	20050113	WO 2004-IB2075	20040621

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-484577P P 20030702
OS MARPAT 142:107448
AB This invention relates to a combination of an allosteric inhibitor of matrix metalloproteinase-13 (MMP-13), or a pharmaceutically acceptable salt thereof, and a ligand to an alpha-2-delta receptor, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the combination, and a method of using the combination to treat a disease or disorder in a mammal responsive to treatment in one aspect by an allosteric inhibitor of MMP-13 and in the same or a different aspect by a ligand to an alpha-2-delta receptor, such as cartilage damage and joint diseases. Preparation of 4-[[3-[2-(4-methoxybenzyl)-2H-tetrazol-5-yl]benzoylamino]methyl]benzoic acid as the allosteric inhibitor of MMP-13 is exemplified.
IT **661486-65-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(combination of allosteric inhibitor of MMP-13 and ligand to alpha-2-delta receptor for treatment of joint disorders)
RN 661486-65-3 CAPLUS
CN Benzoic acid, 4-[[4-[([1,1'-biphenyl]-3-ylmethyl)thio]-3,6-dihydro-5-methyl-2,6-dioxo-1(2H)-pyrimidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **661485-66-1P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(combination of allosteric inhibitor of MMP-13 and ligand to alpha-2-delta receptor for treatment of joint disorders)
RN 661485-66-1 CAPLUS
CN Benzoic acid, 4-[[4-[([1,1'-biphenyl]-3-ylmethyl)thio]-3,6-dihydro-5-methyl-2,6-dioxo-1(2H)-pyrimidinyl]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:857575 CAPLUS
DN 141:332210
TI Preparation of substituted pyrimidinones with ability to inhibit p38 MAP kinase
IN Durley, Richard; Devadas, Balekudru; Madsen, Heather; Hickory, Brian; Palmquist, Katherine; Selness, Shaun
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 363 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004087677	A2	20041014	WO 2004-IB1121	20040329
	WO 2004087677	A3	20041216		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004242608	A1	20041202	US 2004-808146	20040324
	CA 2521081	AA	20041014	CA 2004-2521081	20040329
	NO 2005005092	A	20051101	NO 2005-5092	20051101
PRAI	US 2003-460124P	P	20030403		
	WO 2004-IB1121	W	20040329		

OS MARPAT 141:332210
AB Methods for preparing title compds. I [R1 = H, halo, NO2, CN, (un)substituted-alkyl, -aryl, etc.; R2 = H, OH, halo, (un)substituted-alkyl, -arylalkoxy, -aryloxy, etc.; R4 = H or (un)substituted alkyl; R5 = H, (un)substituted-aryl, -arylalkyl, etc.] and pharmaceutically acceptable salts thereof, are disclosed. Thus, e.g., II was prepared by O and N-benzylation of 4,6-dihydroxypyrimidine with benzyl chloride followed by bromination with N-bromosuccinimide. These compds. are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. I were evaluated via in vitro assays to determine their ability to inhibit human p38 kinase alpha; e.g., II possessed an IC50 value of < 5.00 μM. Pharmaceutical compns. containing the compds., methods of preparing the compds. and methods of treatment using the compds. are also disclosed.
IT **773103-19-8P**
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of pyrimidinone derivs. with p38 MAP kinase activity and ability to regulate TNF)
RN 773103-19-8 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-4-methyl-N-[2-(methylamino)-2-oxoethyl]- (9CI) (CA INDEX NAME)



IT **773103-16-5P 773103-17-6P 773103-20-1P**
773103-21-2P 773103-23-4P 773103-28-9P
773103-30-3P 773103-32-5P 773103-34-7P
773103-83-6P 773103-84-7P 773104-19-1P
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(drug candidate; preparation of pyrimidinone derivs. with p38 MAP kinase activity and ability to regulate TNF)

RN 773103-16-5 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-N,4-dimethyl- (9CI) (CA INDEX NAME)



RN 773103-17-6 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 773103-20-1 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-N-[(2S)-2,3-dihydroxypropyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-21-2 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-N-[(2R)-2,3-dihydroxypropyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-23-4 CAPLUS
CN Benzamide, N-[(1S)-2-amino-1-methyl-2-oxoethyl]-3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-28-9 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-N-[(2S)-2-hydroxypropyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-30-3 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-N-[(2R)-2-hydroxypropyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-32-5 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-N-(2-hydroxyethyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 773103-34-7 CAPLUS
CN Benzamide, N-[(1S)-1-(aminocarbonyl)propyl]-3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-83-6 CAPLUS
CN Benzamide, 3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-N-(2-hydroxyethyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 773103-84-7 CAPLUS

CN Benzamide, N-(2-amino-2-oxoethyl)-3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 773104-19-1 CAPLUS
CN Benzamide, 4-[[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)



IT **773103-82-5P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of pyrimidinone derivs. with p38 MAP kinase activity and ability to regulate TNF)
RN 773103-82-5 CAPLUS
CN Benzoic acid, 3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)



IT **773103-15-4P 773103-18-7P 773103-24-5P 773103-26-7P 773103-35-8P 773103-36-9P**

773103-37-0P 773103-39-2P 773103-41-6P
773103-43-8P 773103-45-0P 773103-47-2P
773103-49-4P 773103-51-8P 773103-52-9P
773103-54-1P 773103-56-3P 773103-57-4P
773103-58-5P 773103-59-6P 773103-60-9P
773103-61-0P 773103-62-1P 773103-63-2P
773103-64-3P 773103-65-4P 773103-66-5P
773103-67-6P 773103-68-7P 773103-69-8P
773103-70-1P 773103-71-2P 773103-72-3P
773103-73-4P 773103-74-5P 773103-75-6P
773103-76-7P 773103-77-8P 773103-78-9P
773103-79-0P 773103-80-3P 773103-81-4P
773103-85-8P 773103-86-9P 773103-87-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrimidinone derivs. with p38 MAP kinase activity and ability to regulate TNF)

RN 773103-15-4 CAPLUS
CN 4(3H)-Pyrimidinone, 5-bromo-6-(phenylmethoxy)-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 773103-18-7 CAPLUS
CN Benzamide, 3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 773103-24-5 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-N-[(1R)-2-hydroxy-1-methylethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-26-7 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-35-8 CAPLUS
CN Benzamide, N-(2-amino-2-oxoethyl)-3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 773103-36-9 CAPLUS
CN Benzamide, 3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-4-methyl-N-[2-(methylamino)-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 773103-37-0 CAPLUS
CN Benzamide, 3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-N-[(2S)-2,3-dihydroxypropyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-39-2 CAPLUS
CN Benzamide, N-[(1S)-2-amino-1-methyl-2-oxoethyl]-3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-41-6 CAPLUS
CN Benzamide, 3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-43-8 CAPLUS
CN Benzamide, 3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-N-(2-hydroxyethyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 773103-45-0 CAPLUS
CN Benzamide, 3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-N-[(1R)-2-hydroxy-1-methylethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-47-2 CAPLUS
CN Benzamide, N-(2-amino-2-oxoethyl)-3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-N,4-dimethyl- (9CI) (CA INDEX NAME)



RN 773103-49-4 CAPLUS
CN Benzamide, 3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-

pyrimidinyl]-N-[(2R)-2,3-dihydroxypropyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-51-8 CAPLUS
CN Benzamide, N-[(1R)-2-amino-1-(hydroxymethyl)-2-oxoethyl]-3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-52-9 CAPLUS
CN Benzamide, N-[(1R)-2-amino-1-methyl-2-oxoethyl]-3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-54-1 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-56-3 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-N-[(1R)-2-hydroxy-1-methylethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-57-4 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-N,4-dimethyl- (9CI) (CA INDEX NAME)



RN 773103-58-5 CAPLUS
CN Benzamide, N-(2-amino-2-oxoethyl)-3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 773103-59-6 CAPLUS
CN Benzamide, N-[(1R)-2-amino-1-methyl-2-oxoethyl]-3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-60-9 CAPLUS
CN Benzamide, N-[(1S)-1-(aminocarbonyl)propyl]-3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-61-0 CAPLUS
CN Benzamide, 3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-N-[(2S)-2-hydroxypropyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-62-1 CAPLUS
CN Benzamide, 3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-N-[(2R)-2-hydroxypropyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-63-2 CAPLUS
CN 3-Pyrrolidinol, 1-[3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-4-methylbenzoyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-64-3 CAPLUS
CN Benzamide, 3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-4-methyl-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)



RN 773103-65-4 CAPLUS
CN Benzamide, 3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-N-(2-methoxyethyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 773103-66-5 CAPLUS
CN Benzamide, 3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-4-methyl-N-[[(2S)-tetrahydro-2-furanyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-67-6 CAPLUS
CN Benzamide, 3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-4-methyl-N-[[(2R)-tetrahydro-2-furanyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-68-7 CAPLUS
CN 3-Pyrrolidinol, 1-[3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-4-methylbenzoyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-69-8 CAPLUS
CN Benzamide, 3-[4-[(2,4-difluorophenyl)methoxy]-5-ethyl-6-oxo-1(6H)-pyrimidinyl]-N-[(1R)-2-hydroxy-1-methylethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-70-1 CAPLUS
CN Benzamide, 3-[4-[(2,4-difluorophenyl)methoxy]-5-ethyl-6-oxo-1(6H)-pyrimidinyl]-N-(2-hydroxyethyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 773103-71-2 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-(methylamino)-6-oxo-1(6H)-pyrimidinyl]-N,4-dimethyl- (9CI) (CA INDEX NAME)



RN 773103-72-3 CAPLUS
CN Benzamide, N-(2-amino-2-oxoethyl)-3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-(methylamino)-6-oxo-1(6H)-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 773103-73-4 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-(methylamino)-6-oxo-1(6H)-pyrimidinyl]-N-[(2S)-2,3-dihydroxypropyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-74-5 CAPLUS
CN Benzamide, 3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-6-oxo-2-(2-propenylamino)-1(6H)-pyrimidinyl]-4-methyl-N-2-propenyl- (9CI) (CA INDEX NAME)



RN 773103-75-6 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-4-methyl-N-[2-(methylamino)-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 773103-76-7 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-N-[(2S)-2,3-dihydroxypropyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-77-8 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-N-[(2R)-2,3-dihydroxypropyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-78-9 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-N-(2-hydroxyethyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 773103-79-0 CAPLUS
CN Benzamide, N-[(1S)-2-amino-1-methyl-2-oxoethyl]-3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-80-3 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-N-[(2S)-2-hydroxypropyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-81-4 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-N-[(2R)-2-hydroxypropyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-85-8 CAPLUS
CN Benzamide, 3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-4-methyl-N-[2-(methylamino)-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 773103-86-9 CAPLUS
CN Benzamide, 3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-N-[(2S)-2-hydroxypropyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773103-87-0 CAPLUS
CN Benzamide, 3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-N-[(2R)-2-hydroxypropyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **773850-54-7P 773850-55-8P 773850-56-9P**
773850-57-0P 773850-58-1P 773850-59-2P
773850-60-5P 773850-61-6P 773850-62-7P
773850-63-8P 773850-64-9P 773850-65-0P
773850-66-1P 773850-67-2P 773850-69-4P
773850-70-7P 773850-71-8P 773850-72-9P
773850-73-0P 773850-74-1P 773850-75-2P
773850-76-3P 773850-77-4P 773850-78-5P
773850-79-6P 773850-80-9P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; stereoselective preparation of pyrimidinone derivs. with p38 MAP kinase activity and ability to regulate TNF via resolution of

atropisomers)

RN 773850-54-7 CAPLUS

CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-4-methyl-N-[2-(methylamino)-2-oxoethyl]-, (-)- (9CI) (CA INDEX NAME)



RN 773850-55-8 CAPLUS

CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-4-methyl-N-[2-(methylamino)-2-oxoethyl]-, (+)- (9CI) (CA INDEX NAME)



RN 773850-56-9 CAPLUS

CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-4-methyl-, (-)- (9CI) (CA INDEX NAME)



RN 773850-57-0 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-4-methyl-, (+)- (9CI) (CA INDEX NAME)



RN 773850-58-1 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-N,4-dimethyl-, (-)- (9CI) (CA INDEX NAME)



RN 773850-59-2 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-N,4-dimethyl-, (+)- (9CI) (CA INDEX NAME)



RN 773850-60-5 CAPLUS
CN Benzamide, N-(2-amino-2-oxoethyl)-3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-4-methyl-, (-)- (9CI) (CA INDEX NAME)



RN 773850-61-6 CAPLUS
CN Benzamide, N-(2-amino-2-oxoethyl)-3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-4-methyl-, (+)- (9CI) (CA INDEX NAME)



RN 773850-62-7 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-N-(2-hydroxyethyl)-4-methyl-, (-)- (9CI) (CA INDEX NAME)



RN 773850-63-8 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-N-(2-hydroxyethyl)-4-methyl-, (+)- (9CI) (CA INDEX NAME)



RN 773850-64-9 CAPLUS
CN Benzamide, 3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-N-(2-hydroxyethyl)-4-methyl-, (-)- (9CI) (CA INDEX NAME)



RN 773850-65-0 CAPLUS
CN Benzamide, 3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-N-(2-hydroxyethyl)-4-methyl-, (+)- (9CI) (CA INDEX NAME)



RN 773850-66-1 CAPLUS
CN Benzamide, N-(2-amino-2-oxoethyl)-3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-4-methyl-, (-)-(9CI) (CA INDEX NAME)



RN 773850-67-2 CAPLUS
CN Benzamide, N-(2-amino-2-oxoethyl)-3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-4-methyl-, (+)-(9CI) (CA INDEX NAME)



RN 773850-69-4 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-N-(2,3-dihydroxypropyl)-4-methyl-, stereoisomer (9CI) (CA INDEX NAME)



RN 773850-70-7 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-N-(2,3-dihydroxypropyl)-4-methyl-, stereoisomer (9CI) (CA INDEX NAME)



RN 773850-71-8 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-N-(2,3-dihydroxypropyl)-4-methyl-, stereoisomer (9CI) (CA INDEX NAME)



RN 773850-72-9 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-N-(2,3-dihydroxypropyl)-4-methyl-, stereoisomer (9CI) (CA INDEX NAME)



RN 773850-73-0 CAPLUS
CN Benzamide, N-(2-amino-1-methyl-2-oxoethyl)-3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-4-methyl-, stereoisomer (9CI) (CA INDEX NAME)



RN 773850-74-1 CAPLUS
CN Benzamide, N-(2-amino-1-methyl-2-oxoethyl)-3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-4-methyl-, stereoisomer (9CI) (CA INDEX NAME)



RN 773850-75-2 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-N-(2-hydroxypropyl)-4-methyl-, stereoisomer (9CI) (CA INDEX NAME)



RN 773850-76-3 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-N-(2-hydroxypropyl)-4-methyl-, stereoisomer (9CI) (CA INDEX NAME)



RN 773850-77-4 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-N-(2-hydroxypropyl)-4-methyl-, stereoisomer (9CI) (CA INDEX NAME)



RN 773850-78-5 CAPLUS
CN Benzamide, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-N-(2-hydroxypropyl)-4-methyl-, stereoisomer (9CI) (CA INDEX NAME)



RN 773850-79-6 CAPLUS
CN Benzamide, N-[1-(aminocarbonyl)propyl]-3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-4-methyl-, stereoisomer (9CI) (CA INDEX NAME)



RN 773850-80-9 CAPLUS
CN Benzamide, N-[1-(aminocarbonyl)propyl]-3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-4-methyl-, stereoisomer (9CI) (CA INDEX NAME)



IT **773103-88-1P 773103-92-7P 773103-93-8P**
773103-94-9P 773103-95-0P 773103-98-3P
773103-99-4P 773104-02-2P 773104-03-3P
773104-04-4P 773104-05-5P 773104-06-6P
773104-07-7P 773104-08-8P 773104-09-9P
773104-10-2P 773104-11-3P 773104-12-4P
773104-13-5P 773104-14-6P 773104-15-7P
773104-16-8P 773104-17-9P 773104-20-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrimidinone derivs. with p38 MAP kinase activity and ability to regulate TNF)

RN 773103-88-1 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(phenylmethoxy)-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 773103-92-7 CAPLUS

CN Benzoic acid, 3-[4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 773103-93-8 CAPLUS
CN Benzoic acid, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 773103-94-9 CAPLUS
CN Benzoic acid, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 773103-95-0 CAPLUS
CN Benzoic acid, 3-[4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 773103-98-3 CAPLUS
CN Benzoic acid, 4-[[4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 773103-99-4 CAPLUS
CN Benzoic acid, 4-[[4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 773104-02-2 CAPLUS
CN Benzoic acid, 3-[4-[(2,4-difluorophenyl)methoxy]-2-(methylthio)-6-oxo-1(6H)-pyrimidinyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 773104-03-3 CAPLUS
CN Benzoic acid, 3-[4-[(2,4-difluorophenyl)methoxy]-2-(methylthio)-6-oxo-1(6H)-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 773104-04-4 CAPLUS
CN Benzamide, 3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-2-(methylthio)-6-oxo-1(6H)-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 773104-05-5 CAPLUS
CN Benzoic acid, 3-[4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 773104-06-6 CAPLUS
CN Benzoic acid, 3-[4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 773104-07-7 CAPLUS
CN Benzoic acid, 3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 773104-08-8 CAPLUS
CN Benzoic acid, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-6-oxo-1(6H)-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 773104-09-9 CAPLUS
CN Benzoic acid, 3-[4-[(2,4-difluorophenyl)methoxy]-5-iodo-6-oxo-1(6H)-pyrimidinyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 773104-10-2 CAPLUS
CN Benzoic acid, 3-[4-[(2,4-difluorophenyl)methoxy]-5-ethenyl-6-oxo-1(6H)-pyrimidinyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 773104-11-3 CAPLUS
CN Benzoic acid, 3-[4-[(2,4-difluorophenyl)methoxy]-5-ethyl-6-oxo-1(6H)-pyrimidinyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 773104-12-4 CAPLUS
CN Benzoic acid, 3-[4-[(2,4-difluorophenyl)methoxy]-5-ethyl-6-oxo-1(6H)-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 773104-13-5 CAPLUS
CN Benzoic acid, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-(methylsulfonyl)-6-oxo-1(6H)-pyrimidinyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 773104-14-6 CAPLUS
CN Benzoic acid, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-(methylamino)-6-oxo-1(6H)-pyrimidinyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 773104-15-7 CAPLUS
CN Benzoic acid, 3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-(methylamino)-6-oxo-1(6H)-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 773104-16-8 CAPLUS
CN Benzoic acid, 3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-2-(methylsulfonyl)-6-oxo-1(6H)-pyrimidinyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 773104-17-9 CAPLUS
CN Benzoic acid, 3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-6-oxo-2-(2-propenylamino)-1(6H)-pyrimidinyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 773104-20-4 CAPLUS
CN Benzoic acid, 3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-6-oxo-2-(2-propenylamino)-1(6H)-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)



IT **773104-18-0**
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process)
(starting material; preparation of pyrimidinone derivs. with p38 MAP kinase activity and ability to regulate TNF)
RN 773104-18-0 CAPLUS
CN Benzamide, N-(2-amino-2-oxoethyl)-3-[5-bromo-4-[(2,4-difluorophenyl)methoxy]-2-methyl-6-oxo-1(6H)-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:716288 CAPLUS
DN 141:218924
TI Antiviral agents containing nitrogen-containing heteroaromatic compounds
IN Fuji, Masahiro; Matsushita, Shihaku; Mikamiyama, Hidenori
PA Shionogi and Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 54 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2004244320	A2	20040902	JP 2003-32772	20030210
PRAI JP 2003-32772		20030210		

OS MARPAT 141:218924
AB The invention provides antiviral agents having HIV integrase inhibitory effects, characterized by containing I [G1 = (substituted) N,; G2 = (substituted) C; G3 = (substituted)N, C, O, S; R1 = (substituted) aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycle; V1, V3 = (substituted) alkylene, alkenylene; V2 = (substituted) alkylene, alkenylene, etc.; X = O, S, NH; Y = hydroxy, mercapto, amino; Z = O, S, NH]. A compound II was prepared, and in vitro tested for its HIV integrase inhibitory effect. A capsule containing an active component 250 mg/capsule was also formulated.
IT **745803-46-7P 745803-48-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of antiviral agents having HIV integrase inhibitory effects containing nitrogen-containing heteroarom. compds.)
RN 745803-46-7 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-1-[(4-methoxyphenyl)methyl]-2-methyl-6-oxo-5-(phenylmethoxy)-, ethyl ester (9CI) (CA INDEX NAME)



RN 745803-48-9 CAPLUS
CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-1-[(4-methoxyphenyl)methyl]-2-methyl-6-oxo-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)


MeO
Me
CH2
N
N
O
C
NH
CH2
F
O
Ph
CH2
O

L4 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:143115 CAPLUS
DN 140:199336
TI Preparation of pyrimidine-2,4-diones as matrix metalloproteinase inhibitors
IN Hicks, James Lester; Roark, William Howard
PA Warner-Lambert Company Llc, USA
SO PCT Int. Appl., 140 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004014868	A2	20040219	WO 2003-IB3525	20030804
	WO 2004014868	A3	20040603		
	WO 2004014868	C1	20040729		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2497656	AA	20040219	CA 2003-2497656	20030804
	AU 2003250471	A1	20040225	AU 2003-250471	20030804
	BR 2003013385	A	20050614	BR 2003-13385	20030804
	EP 1553949	A2	20050720	EP 2003-784400	20030804
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006500351	T2	20060105	JP 2004-527212	20030804
	US 2004053952	A1	20040318	US 2003-634419	20030805
PRAI	US 2002-403023P	P	20020813		
	WO 2003-IB3525	W	20030804		

OS MARPAT 140:199336
AB The title compds. [I; R1 = cycloalkyl(alkylenyl)m, phenyl(alkylenyl)m, naphthyl(alkylenyl)m, etc.; R2 = H, alkyl, phenyl(alkylenyl)m, etc.; R3 = H, Me, OMe, etc.; R4, R5 = H, alkyl; Q = O, S, SO, SO2, NR5; m = 0-1], useful for inhibiting an MMP-13 enzyme, were prepared Thus, reacting 3-benzyl-6-mercapto-5-methyl-1H-pyrimidine-2,4-dione (preparation given) with 2-bromo-6-methoxybenzothiazole afforded 3-benzyl-6-(6-methoxybenzothiazol-2-ylamino)-5-methyl-1H-pyrimidine-2,4-dione which showed IC50 of about 0.44 μM against MMP-13. The invention also provides pharmaceutical compns. comprising a compound I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient,

comprising administering to the patient a compound I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition The invention also provides combinations, comprising a compound I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.

IT **661486-07-3P 661486-13-1P 661486-18-6P**
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine-2,4-diones as matrix metalloproteinase inhibitors)

RN 661486-07-3 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 6-[[[4-chloro-2-(trifluoromethyl)-6-quinolinyl]methyl]thio]-5-methyl-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 661486-13-1 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 5-methyl-6-[(2-naphthalenylmethyl)thio]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 661486-18-6 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 6-[([1,1'-biphenyl]-2-ylmethyl)thio]-5-methyl-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT **661485-67-2P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrimidine-2,4-diones as matrix metalloproteinase inhibitors)

RN 661485-67-2 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 6-[([1,1'-biphenyl]-3-ylmethyl)thio]-5-methyl-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT **661485-66-1P 661485-68-3P 661485-69-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine-2,4-diones as matrix metalloproteinase inhibitors)

RN 661485-66-1 CAPLUS

CN Benzoic acid, 4-[[4-[([1,1'-biphenyl]-3-ylmethyl)thio]-3,6-dihydro-5-methyl-2,6-dioxo-1(2H)-pyrimidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 661485-68-3 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 6-[([1,1'-biphenyl]-3-ylmethyl)sulfinyl]-5-methyl-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 661485-69-4 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 6-[([1,1'-biphenyl]-4-ylmethyl)thio]-5-methyl-

3-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT **661486-65-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidine-2,4-diones as matrix metalloproteinase inhibitors)
RN 661486-65-3 CAPLUS
CN Benzoic acid, 4-[[4-[([1,1'-biphenyl]-3-ylmethyl)thio]-3,6-dihydro-5-methyl-2,6-dioxo-1(2H)-pyrimidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:381455 CAPLUS
DN 133:17483
TI Preparation of angiotensin II receptor antagonistic 1,2,4-triazin-5-one derivatives
IN Yang, Paw-Hwa; Lee, Pei-Ling; Chou, Shan-Yen; Wang, Chia-Lin; Lu, Hsiao-Hwa
PA Development Center for Biotechnology, Taiwan
SO U.S., 12 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6071913	A	20000606	US 1997-987039	19971209
TW 418204	B	20010111	TW 1997-86103987	19970328
PRAI TW 1997-86103987	A	19970328		

OS MARPAT 133:17483
AB 1,2,4-Triazin-5-one biphenyl derivs. I [R1 = alkyl, cycloalkyl, aryl; R2 = alkyl, aryl, arylalkyl; A, D = CR3, N, NH, C(O); R3 = H, dialkylphosphonate, halo], useful as non-peptide antagonists of angiotensin II receptor, were prepared E.g., 6-methyl-3-phenyl-5-oxo-2-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1,2,4-triazine was prepared
IT **223927-32-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of angiotensin II receptor antagonistic 1,2,4-triazin-5-one derivs.)
RN 223927-32-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-butyl-6-chloro-5-(2-phenylethyl)-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:158847 CAPLUS
DN 130:325133
TI The syntheses of triazinone and pyrimidinone biphenyltetrazoles as angiotensin II receptor antagonists
AU Chou, Shan-Yen; Yang, Paw-Hwa; Wang, Chia-Lin J.; Lu, Hsiao-Hwa; Chen, Yin; Kao, Jen-Mann
CS Natural Product and Medicinal Chemistry Division, Pharmaceutical R & D Laboratories, Development Center for Biotechnology, Taipei Hsien, Taiwan
SO Journal of the Chinese Chemical Society (Taipei) (1999), 46(1), 53-62
CODEN: JCCTAC; ISSN: 0009-4536
PB Chinese Chemical Society
DT Journal
LA English
AB A series of biphenylyltetrazole substituted triazinones and structure-related pyrimidinones are synthesized, and their binding affinities for angiotensin II receptor are reported.
IT **223927-01-3P 223927-03-5P 223927-05-7P**
223927-07-9P 223927-23-9P 223927-32-0P
223927-34-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of [[(tetrazolyl)biphenylyl]methyl]triazinones and [(tetrazolyl)biphenylyl]methyl]pyrimidinones as angiotensin II antagonists)
RN 223927-01-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-butyl-6-methoxy-5-(2-phenylethyl)-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 223927-03-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-butyl-6-ethoxy-5-(2-phenylethyl)-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 223927-05-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-butyl-6-[(methylsulfonyl)oxy]-5-(2-phenylethyl)-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 223927-07-9 CAPLUS
CN Phosphoric acid, 2-butyl-1,6-dihydro-6-oxo-5-(2-phenylethyl)-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-4-pyrimidinyl diethyl ester (9CI) (CA INDEX NAME)



RN 223927-23-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-butyl-6-(2-phenylethyl)-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 223927-32-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-butyl-6-chloro-5-(2-phenylethyl)-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 223927-34-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-butyl-5-(2-phenylethyl)-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:621674 CAPLUS
DN 129:343462
TI Synthesis of tricarbonylmethane derivatives of pyridines, pyrimidines, pyridazines, and pyrazoles by anionic ortho-Fries rearrangement
AU Schnell, Barbara; Kappe, Thomas
CS Institute Organic Chemistry, Karl Franzens University, Graz, A-8010, Austria
SO Monatshefte fuer Chemie (1998), 129(8/9), 871-885
CODEN: MOCMB7; ISSN: 0026-9247
PB Springer-Verlag Wien
DT Journal
LA English
OS CASREACT 129:343462
AB Heterocyclic 1,3-dicarbonyl systems, such as 4-hydroxy-2-pyridones, 6-hydroxy-4-pyrimidones, and 5-hydroxy-1-phenyl-3-pyrazolones, are converted with a number of aromatic acid chlorides to their enol esters which can be rearranged in the presence of KCN, Et3N, and 18-crown-6 as catalyst to yield heterocyclic aryl ketones. This reaction can also be performed in a 1-pot procedure without isolation of the esters. Aryl esters of 5-hydroxy-3-pyridazinone are prepared in the same manner, but can not be rearranged.
IT **215609-28-2P 215609-31-7P 215609-32-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tricarbonylmethane derivs. of pyridines, pyrimidines, pyridazines, and pyrazoles by anionic ortho-Fries rearrangement)
RN 215609-28-2 CAPLUS
CN Benzoic acid, 4-chloro-, 1,6-dihydro-6-oxo-1,2-diphenyl-4-pyrimidinyl ester (9CI) (CA INDEX NAME)



RN 215609-31-7 CAPLUS
CN Benzoic acid, 4-chloro-2-nitro-, 1,6-dihydro-6-oxo-1,2-diphenyl-4-pyrimidinyl ester (9CI) (CA INDEX NAME)



RN 215609-32-8 CAPLUS
CN Benzoic acid, 4-methyl-, 1,6-dihydro-6-oxo-1,2-diphenyl-4-pyrimidinyl ester (9CI) (CA INDEX NAME)



IT **215609-27-1P 215609-29-3P 215609-30-6P**
215609-33-9P 215609-34-0P 215609-35-1P
215609-36-2P 215609-37-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of tricarbonylmethane derivs. of pyridines, pyrimidines, pyridazines, and pyrazoles by anionic ortho-Fries rearrangement)
RN 215609-27-1 CAPLUS
CN 4(3H)-Pyrimidinone, 6-(benzoyloxy)-2,3-diphenyl- (9CI) (CA INDEX NAME)



RN 215609-29-3 CAPLUS
CN Benzoic acid, 2-chloro-, 1,6-dihydro-6-oxo-1,2-diphenyl-4-pyrimidinyl ester (9CI) (CA INDEX NAME)



RN 215609-30-6 CAPLUS
CN Benzoic acid, 2-bromo-, 1,6-dihydro-6-oxo-1,2-diphenyl-4-pyrimidinyl ester (9CI) (CA INDEX NAME)



RN 215609-33-9 CAPLUS
CN Benzoic acid, 4-methoxy-, 1,6-dihydro-6-oxo-1,2-diphenyl-4-pyrimidinyl

ester (9CI) (CA INDEX NAME)



RN 215609-34-0 CAPLUS
CN Benzoic acid, 2,4-dichloro-, 1,6-dihydro-6-oxo-1,2-diphenyl-4-pyrimidinyl ester (9CI) (CA INDEX NAME)



RN 215609-35-1 CAPLUS
CN Benzoic acid, 2,3-dichloro-4-(methylsulfonyl)-, 1,6-dihydro-6-oxo-1,2-diphenyl-4-pyrimidinyl ester (9CI) (CA INDEX NAME)



RN 215609-36-2 CAPLUS
CN Benzoic acid, 2-methyl-, 1,6-dihydro-6-oxo-1,2-diphenyl-4-pyrimidinyl ester (9CI) (CA INDEX NAME)



RN 215609-37-3 CAPLUS
CN Benzoic acid, 3-methoxy-2-methyl-4-(methylsulfonyl)-, 1,6-dihydro-6-oxo-

1,2-diphenyl-4-pyrimidinyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:117866 CAPLUS
DN 126:220291
TI Synthesis, antiviral and antiproliferative activity of a new class of 5-(alkyl or arylthio)-6-vinyl uracils
AU Baraldi, Pier Giovanni; Cacciari, Barbara; Romagnoli, Romeo; Spalluto, Giampiero; Garuti, Laura; Roberti, Marinella; Pani, Alessandra; Perra, Graziella; Scintu, Franca; Pinna, Noemi; Musiu, Chiara; La Colla, Paolo
CS Dip. Sci. Farmaceutiche, Ferrara, I-44100, Italy
SO Anti-Cancer Drug Design (1996), 11(8), 597-609
CODEN: ACDDEA; ISSN: 0266-9536
PB Oxford University Press
DT Journal
LA English
AB Uracil derivs. bearing substituted or unsubstituted vinyl groups at position C6 and alkyl- or arylthio groups at position C5 were synthesized and tested in vitro for antiviral and antiproliferative activity. None of the compds. were active against HIV-1. However, some of them inhibited the proliferation of leukemia, lymphoma and solid tumor-derived cell lines at micromolar concns. The maximum potency of antiproliferative activity correlates with the presence of unsubstituted vinyl groups and alkyl- or arylthio substituents.
IT **188395-73-5P 188395-74-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis, antiviral and antiproliferative activity of 5-(alkyl or arylthio)-6-vinyl uracils)
RN 188395-73-5 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 3-phenyl-5-[(phenylmethyl)thio]-6-(1-propenyl)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.





RN 188395-74-6 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 3-phenyl-6-(2-phenylethenyl)-5-[(phenylmethyl)thio]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


O
Ph
N
NH
E
O
Ph
Ph
S

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:397831 CAPLUS
DN 123:169573
TI Unusual Ring-Opening Reaction of 6,7-Dihydrothieno[3,2-d]pyrimidine-2,4-dione Derivatives Leading to 5-(Alkylthio)-6-vinyluracils
AU Baraldi, Pier Giovanni; Cacciari, Barbara; Manfredini, Stefano; Pollini, Gian Piero; Simoni, Daniele; Spalluto, Giampiero; Zanirato, Vinicio
CS Dipartimento di Scienze Farmaceutiche, Universita di Ferrara, Ferrara, 17-19, Italy
SO Journal of Organic Chemistry (1995), 60(5), 1461-3
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
OS CASREACT 123:169573
AB The reaction of 6,7-dihydrothieno[3,2-d]pyrimidine-2,4-dione (I, R1, R3 = H, Ph; R2 = H, Me) with organic halides in the presence of dilute sodium hydroxide gave rise to a β-sulfonium elimination reaction to afford 6-vinyl-5-(alkylthio)pyrimidines (II). Starting compds. are conveniently prepared from the unknown 3-amino-2-methoxycarbonyl-4,5-dihydrothiophene derivs., in turn obtained by Michael-Thorpe-Ziegler cyclization between acrylonitriles and Me thioglycolate in presence of sodium methoxide in methanol at room temperature
IT **167280-89-9P 167280-90-2P 167280-91-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of vinyluracils by ring-opening of thienopyrimidinediones)
RN 167280-89-9 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 6-ethenyl-3-phenyl-5-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)





RN 167280-90-2 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 3-phenyl-6-(2-phenylethenyl)-5-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



RN 167280-91-3 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 6-(1-methylethenyl)-3-phenyl-5-

[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1991:247301 CAPLUS
DN 114:247301
TI Preparation of 2-alkyl-1,6-dihydro-1-(biphenylylalkyl)-6-oxopyrimidines as angiotensin II antagonists
IN Herold, Peter; Buehlmayer, Peter
PA Ciba-Geigy A.-G., Switz.
SO Eur. Pat. Appl., 46 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 407342	A2	19910109	EP 1990-810482	19900627
	EP 407342	A3	19910710		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	CA 2020370	AA	19910107	CA 1990-2020370	19900704
	AU 9058696	A1	19910110	AU 1990-58696	19900704
	AU 637617	B2	19930603		
	JP 03044377	A2	19910226	JP 1990-177673	19900706
PRAI	CH 1989-2509	A	19890706		

OS MARPAT 114:247301
AB Title compds. [I; Z = O, S, NR; R = H, aliphatyl; R1 = (substituted) aliphatyl, cycloaliphatyl, arylaliphatyl, aryl; R2, R3 = halo, acyl, aryl, amino, (modified) carboxy; or R2 = Z1R4; R3 = Z2R5; Z1, Z2 = bond, O, S, SO, SO2; R4, R5 = H, arylaliphatyl, (substituted) (O-, S-, SO or SO2-interrupted) aliphatyl; R2R3 = (CH2)3, (CH2)4, CH:CHCH:CH, etc.; R6 = Q1; X3 = aliphatylene; R7 = CO2H, SO3H, haloalkylsulfony, PO2H2, PO3H2, 5-tetrazolyl] were prepared Thus, 2-butyl-4-chloro-6-hydroxypyrimidine NaH, and 4-bromomethyl-2'-cyanobiphenyl were stirred 12 h in DMF and the coupling product was hydrogenated in MeOH containing Et3N over Pd/C to give 2-butyl-1,6-dihydro-1-[(2'-cyanobiphenyl-4-yl)methyl]-6-oxopyrimidine. The latter was refluxed 24 h with Bu3SnN3 in o-xylene to give title compound II. Tablets were prepared containing II. I inhibited angiotensin II-induced hypertension in rats at ≥0.3 mg/kg i.v.
IT **134075-64-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as angiotensin II antagonist)
RN 134075-64-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-butyl-6-(phenylmethoxy)-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



IT **134075-99-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as intermediate for angiotensin II antagonist)
RN 134075-99-3 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[2-butyl-6-oxo-4-(phenylmethoxy)-1(6H)-pyrimidinyl]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1982:501174 CAPLUS
DN 97:101174
TI X-ray and photoelectron spectroscopic studies on chemical compounds
AU Szargan, R.; Meisel, A.
CS Sekt. Chem., Karl-Marx-Univ., Leipzig, Ger. Dem. Rep.
SO Recent Adv. Anal. Spectrosc., Proc. Int. Conf. At. Spectrosc., 9th (1982), Meeting Date 1981, 175-84. Editor(s): Fuwa, Keiichiro. Publisher: Pergamon, Oxford, UK.
CODEN: 48AYAC
DT Conference
LA German
AB The mol. structure is correlated to chemical shifts of N1s and S2p binding energies and the intensity distribution curves of S Kβ emission bands in various organic compds. and ligands in transition metal complexes. Conjugative effects are shown to influence the N1s binding energies in compds. containing amino groups, and the charge distribution in neutral and mesoionic N-heterocycles and betaines. The correlation between chemical bond and S Kβ intensity distribution in compds. containing thioether and thione functions is reviewed and some new examples of S3p delocalization due to S lone pair -π interaction with aromatic systems are reported. The coordination in neutral bis- and tris-complexes of 1,3-dichalcogen and aza-isosteric systems with numerous metal ions is characterized by means of the measured low-energy shift of the N1s binding energy due to deprotonation of the ligand and a pos. shift of the S2p binding energy due to sulfur-metal donor bond. An addnl. structure on the high-energy side and a broadening of the S Kβ band confirm the interaction between the S lone pair and the metal d electrons.
IT **60139-28-8**
RL: PRP (Properties)
(photoelectron spectrum of, mol. structure in relation to binding energies of)
RN 60139-28-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2,3-diphenyl-6-(phenylmethoxy)-5-(phenylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1981:191090 CAPLUS
DN 94:191090
TI Mesoionic six-membered-ring heterocycles. XIII. ESCA studies of charge distribution in mesoionic pyrimidines and 1,3,5-triazines
AU Szargan, Ruediger; Kappe, Thomas
CS Sekt. Chem., Karl-Marx-Univ., Leipzig, DDR 7010, Ger. Dem. Rep.
SO Zeitschrift fuer Chemie (1980), 20(12), 441-2
CODEN: ZECEAL; ISSN: 0044-2402
DT Journal
LA German
AB The photoelectron spectra of I (R = Ph, PhCH2), II (same R), and III were compared with those of related uncharged mols. The N 1s binding energies of I and II were 401.1-401.5 eV. III exhibited 2 peaks at 401.0 eV (pos. charged N) and 398.7 (uncharged N).
IT **60139-28-8**
RL: PRP (Properties)
(binding energy of nitrogen electron in)
RN 60139-28-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2,3-diphenyl-6-(phenylmethoxy)-5-(phenylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1976:494304 CAPLUS
DN 85:94304
TI Mesoionic six-membered heterocycles, VI. Rearrangement reactions of heterocycles, IV. Thermal rearrangement of mesoionic N-benzylpyrimidines
AU Schindler, Gerda; Furtunopulos, Demetrius; Kappe, Thomas
CS Inst. Org. Chem., Univ. Graz, Graz, Austria
SO Zeitschrift fuer Naturforschung, Teil B: Anorganische Chemie, Organische Chemie (1976), 31B(4), 500-4
CODEN: ZNBAD2; ISSN: 0340-5087
DT Journal
LA German
AB The zwitterion I on pyrolysis underwent benzyl group N→O migration to give the ether II in poor yield, whereas the pyrimidine III gave the N→C migration product IV.
IT **60139-28-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 60139-28-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2,3-diphenyl-6-(phenylmethoxy)-5-(phenylmethyl)- (9CI) (CA INDEX NAME)



```
=> => d his

     (FILE 'HOME' ENTERED AT 07:50:33 ON 20 MAR 2006)

     FILE 'REGISTRY' ENTERED AT 07:50:41 ON 20 MAR 2006
L1                STRUCTURE UPLOADED
L2              1 S L1 SSS SAM
L3            150 S L1 SSS FUL

     FILE 'CAPLUS' ENTERED AT 07:53:15 ON 20 MAR 2006
L4             15 S L3

     FILE 'CAOLD' ENTERED AT 07:53:56 ON 20 MAR 2006

=> s l3
L5              0 L3

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY   SESSION
FULL ESTIMATED COST                                    0.44     246.02

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY   SESSION
CA SUBSCRIBER PRICE                                    0.00     -11.25

STN INTERNATIONAL LOGOFF AT 07:54:11 ON 20 MAR 2006
```